Mark Bamforth work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Mark Bamforth personal email
Mark Bamforth phone numbers
Mark Bamforth is a CEO and Board Chair at Kincell Bio. He possess expertise in biotechnology, biopharmaceuticals, pharmaceutical industry, technology transfer, leadership and 15 more skills. Colleagues describe him as "Mark is one of the most principled people I’ve had the pleasure of knowing in my life. He is competent, of deep intelligent, strength of character, resilient, and loyal to family and his history. Characteristics hard to find in todays world!"
-
Ceo And Board ChairKincell BioBoston, Ma, Us
-
Member Board Of DirectorsAmr Newco May 2024 - PresentDriving innovation in antibacterial drug discovery, our AMR NewCo, created by Kineticos through its AMR Accelerator Fund (KAMRA), is developing a new class of broad spectrum antibacterials to treat drug resistant infections. Building upon decades of groundbreaking research from one of the world’s leading Universities, our team has developed a novel class of antibiotics with the unique potential to treat even the most challenging drug-resistant infections. Our mission is clear: safeguard the future of modern medicine through the development of a robust pipeline of innovative antibiotics to treat patients with hospital- and community-acquired infections.
-
Member Of The General Partners, Kineticos Amr Accelerator Fund IKineticos Ventures Jul 2023 - PresentKineticos AMR Accelerator (KAMRA) Fund I seeks to invest in early-stage anti-microbial resistance (AMR) businesses with founders who have created unique, innovative and know-how protected products and services to address this global healthcare challenge.
-
FounderThairm Bio May 2022 - PresentThairm Bio is an investor in life science entrepreneurs and disruptive companies
-
Executive AdvisorAmpersand Capital Partners Feb 2023 - PresentWellesley, Ma, Us -
Operating PartnerAmpersand Capital Partners Jul 2018 - Jan 2023Wellesley, Ma, UsAmpersand was founded in the late 1980s and began investing in healthcare in the early 1990s. Today, Ampersand is focused exclusively on growth equity investments in lower middle market healthcare companies. We are typically the first institutional investor in founder-owned businesses, where we work with the entrepreneur to help take the company to the next level.
-
Board MemberContinuus Pharmaceuticals Sep 2019 - PresentWoburn, Massachusetts, Us -
Board MemberEnterobiotix Dec 2019 - Present -
TrusteeEntrepreneurial Scotland 2007 - PresentGlasgow, Scotland, GbTrustee of a charity which aims to increase leadership talent in Scottish businesses -
Venture PartnerKineticos Life Sciences Dec 2021 - PresentKineticos Ventures invests in biotechs striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. The Kineticos Ventures fund focuses on significant, unmet medical needs in oncology, neurosciences, and rare diseases, utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced."
-
Board MemberPneumagen Limited May 2020 - PresentSt. Andrews, Gb -
Board MemberInceptor Bio Mar 2021 - Apr 2023Morrisville, North Carolina, Us -
Exec. Chair & CeoArranta Bio Aug 2019 - Apr 2022Watertown, Ma, UsFounded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled expertise are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across two sites with three distinct technology platforms designed to meet the evolving demands of our clients and partners. Additional information about Arranta Bio is available at www.arrantabio.com -
Board MemberAvid Bioservices Oct 2017 - Jul 2021Tustin, California, Us -
Board MemberMassbio 2002 - Feb 2021Cambridge, Massachusetts, UsBoard Member of MassBio, which represents the biotech industry in MA -
President & CeoBrammer Bio Mar 2015 - Jul 2019Cambridge, Massachusetts, UsBrammer Bio is a CDMO focused on providing process development, clinical, and commercial supply of viral vector and cell and gene therapy products, enabling the delivery of novel medicines and improving patient health. We have a highly skilled team of scientists with the development, manufacturing and analytical expertise from 100 client projects that is required to tackle the challenges posed by these novel technologies and help accelerate their transition from the clinic to patients in need while focusing on meeting cGMP standards. Brammer Bio has the expertise to support your gene and cell therapy projects to Phase III and beyond. -
President & CeoGallus Biopharmaceuticals Sep 2010 - Mar 2015St. Louis, Mo, UsMark Bamforth founded and led Gallus BioPharmaceuticals, a premier contract manufacturer, to deliver clinical and commercial biopharmaceuticals in 2010. Gallus began with the acquisition of a world-class facility with an outstanding team in St. Louis, MO, in 2011, making two lead commercial products for Janssen (J&J). Since then, Gallus grew strongly through organic growth and a merger with another CMO, Laureate Biopharma, based in Princeton, NJ, in 2013, to a team of 400 employees in 2014, serving 8 out of the top 15 pharma companies and many mid-sized and emerging biotechs.Bamforth managed the sale of Gallus to DPx Holdings (aka Patheon) in Sept. 2014 and supported the integration through March 2015. -
Svp, Corporate Operations & PharmaceuticalsGenzyme Corporation Apr 1988 - Sep 2010Paris, France, FrGlobal manufacturing operations leader and corporate officer -
Chemical EngineerWhitbread Plc 1986 - 1988QC of beer and biotech project leader
-
Petroleum EngineerBritoil Plc Aug 1984 - Sep 1986Offshore oil exploration and production
Mark Bamforth Skills
Mark Bamforth Education Details
-
Henley Business SchoolMaster Of Business Administration (Mba) -
University Of StrathclydeChemical Engineering
-
Shawlands Academy, Glasgow
Frequently Asked Questions about Mark Bamforth
What company does Mark Bamforth work for?
Mark Bamforth works for Kincell Bio
What is Mark Bamforth's role at the current company?
Mark Bamforth's current role is CEO and Board Chair.
What is Mark Bamforth's email address?
Mark Bamforth's email address is ma****@****bio.com
What is Mark Bamforth's direct phone number?
Mark Bamforth's direct phone number is +131442*****
What schools did Mark Bamforth attend?
Mark Bamforth attended Henley Business School, University Of Strathclyde, Shawlands Academy, Glasgow.
What skills is Mark Bamforth known for?
Mark Bamforth has skills like Biotechnology, Biopharmaceuticals, Pharmaceutical Industry, Technology Transfer, Leadership, Life Sciences, Strategic Planning, Lifesciences, Drug Development, Start Ups, Medical Devices, Process Simulation.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial